Potential New Therapeutic Approaches for Myelofibrosis
暂无分享,去创建一个
[1] D. Niederwieser,et al. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Mead,et al. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. , 2021, Future oncology.
[3] Kaori Ito,et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. , 2020, Blood advances.
[4] A. Mead,et al. Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study , 2020 .
[5] S. Verstovsek,et al. The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis , 2020 .
[6] P. Trojer,et al. MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients , 2020, Blood.
[7] S. Verstovsek,et al. A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor , 2020 .
[8] H. Dai,et al. Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma , 2020 .
[9] S. Verstovsek,et al. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms , 2020, Cancers.
[10] Angela G. Fleischman,et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. , 2020, Blood advances.
[11] S. Verstovsek,et al. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives , 2020, HemaSphere.
[12] R. Mesa,et al. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression. , 2020, Blood reviews.
[13] S. Verstovsek,et al. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. , 2020, Clinical lymphoma, myeloma & leukemia.
[14] R. Foà,et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis , 2019, Cancer.
[15] H. Kantarjian,et al. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis , 2018, European journal of haematology.
[16] B. Bernstein,et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. , 2018, Cancer cell.
[17] H. Kantarjian,et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. , 2017, Blood.